Stay updated with breaking news from William Doyle. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Final data from the METIS study anticipated in 2024 Novocure (NASDAQ: NVCR) today announced that the final patient has enrolled in the pivotal METIS study evaluating the efficacy of Tumor Treating
Dr. Ocean, a medical oncologist and Associate Professor of Clinical Medicine at Weill Cornell Medicine, brings decades of experience in oncology to Novocure Novocure (NASDAQ: NVCR) today announced
Full year 2022 net revenues of $538 million and fourth quarter net revenues of $128 million Pivotal LUNAR study in non-small cell lung cancer met primary overall survival endpoint and a key secondary
NVCR earnings call for the period ending December 31, 2022.
Novocure (Nasdaq:NVCR) shares took a hit today on fourth-quarter results that came in mixed compared to the consensus forecast.